logo
Share SHARE
FONT-SIZE Plus   Neg

New York Community Bancorp Q1 Profit Down - Quick Facts

New York Community Bancorp Inc. (NYB) reported that its first-quarter GAAP earnings were $118.3 million, or $0.27 per share, down from $123.2 million, or $0.28 per share in the year ago quarter. Analysts polled by Thomson Reuters expected the company to report earnings of $0.26 per share. Analysts' estimates typically exclude special items.

Operating earnings totaled $117.8 million or $0.27 per share, compared to $117.2 million or $0.27 per share in the year ago quarter.

Net interest income for the quarter declined to $288.41 million from $303.25 million in the prior year quarter. Total non-interest income was $61.99 million, up from $58.61 million in year ago quarter.

The company said that its board declared quarterly cash dividend of $0.25 per share. The dividend is payable on May 17th to shareholders of record at the close of business on May 7, 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT